Karen Reckamp, MD

Articles

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

August 1st 2021

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Dr. Reckamp on MET-Targeting Strategies in NSCLC

July 27th 2018

Karen Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, medical director, Clinical Research Operations, professor, Department of Medical Oncology & Therapeutics Research, thoracic oncologist, discusses current and emerging therapeutic strategies to target MET in non-small cell lung cancer.

Dr. Reckamp on MK-2206 for the Treatment of EGFR Wild-Type NSCLC

July 28th 2014

Karen L. Reckamp, MD, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Dr. Reckamp Evaluates the Predictive Efficacy of VeriStrat

September 14th 2012

Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.

Dr. Reckamp Discusses the Use of Hsp90 Inhibitors

August 25th 2011

Dr. Karen Reckamp from the City of Hope Cancer Center Discusses the Use of Hsp90 Inhibitors

Dr. Reckamp on Current Heat Shock Protein Clinical Trials

August 22nd 2011

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

Dr. Reckamp Describes the Use of Heat Shock Proteins

August 19th 2011

Dr. Karen Reckamp from City of Hope Cancer Center Describes the Use of Heat Shock Proteins

Dr. Reckamp Discusses Heat Shock Proteins in Lung Cancer

August 17th 2011

Dr. Karen Reckamp from City of Hope Cancer center Discusses Heat Shock Proteins in Lung Cancer